Amarin (AMRN +1%) gains after saying it's submitted a Supplemental New Drug Application with the FDA seeking approval for the marketing and sale of Vascepa capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides with mixed dyslipidemia. The drug is already approved to treat hypertriglyceridemia, and if cleared for the new indication, it will be the only approved prescription omega 3 therapy for cardiovascular health management in this patient population.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:45AM)
at Zacks.com (Feb 23, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs